Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 8/20 | 0.43 |
| ▸ | ELANE | P08246 | 8/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.42 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16663358 | 0.84 | PIK3CD (0.45) | PIK3CDPIK3R1PARP1PIK3R2 | |
| SCHEMBL28833248 | 0.82 | PIK3CD (0.51) | PIK3CDELANEPIK3R2 | |
| SCHEMBL28833247 | 0.82 | PIK3CD (0.51) | PIK3CDELANEPIK3R2 | |
| SCHEMBL15812924 | 0.81 | PIK3CD (0.60) | PIK3CDPIK3R1 | |
| SCHEMBL16630527 | 0.81 | PIK3CD (0.52) | PIK3CDPIK3R1PIK3R2 | |
| SCHEMBL20717712 | 0.81 | PIK3CD (0.64) | PIK3CDPIK3R1 | |
| SCHEMBL754017 | 0.81 | PIK3CD (0.64) | PIK3CDPIK3R1 | |
| SCHEMBL15812927 | 0.81 | PIK3CD (0.60) | PIK3CDPIK3R1 | |
| SCHEMBL7013206 | 0.78 | SMN1; SMN2 (0.49) | PIK3CDELANEPARP1CTRB1CASR | |
| SCHEMBL7014708 | 0.78 | ELANE (0.49) | PIK3CDELANEPARP1CTRB1CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359365-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150111874-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111874-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885ELANE 1219/4885PIK3R1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.